Akebia Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Akebia Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-6.9%
Buyback Yield
| Total Shareholder Yield | -6.9% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%
Nov 08
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Aug 02Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 05Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump
Jun 23Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky
Oct 07Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher
Aug 10Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Jun 30Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if AKBA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AKBA's dividend payments have been increasing.
Dividend Yield vs Market
| Akebia Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (AKBA) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (AKBA) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate AKBA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AKBA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate AKBA's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AKBA has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 04:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Akebia Therapeutics, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Aegis Capital Corporation |
| Jonathan Aschoff | Brean Capital |
| Jonathan Aschoff | B. Riley Wealth |